Seres Therapeutics, Inc.
MCRB
$9.31
-$0.77-7.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -93.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -93.44% |
| Cost of Revenue | 70.08% | -37.71% | -61.80% | -50.64% | -93.48% |
| Gross Profit | -70.08% | 37.71% | -122.43% | 51.22% | 93.34% |
| SG&A Expenses | -10.86% | -34.59% | -42.75% | -31.17% | -37.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -222.93% | -32.96% | -- |
| Total Operating Expenses | -22.12% | -34.58% | -59.27% | -43.49% | -46.56% |
| Operating Income | 22.12% | 34.58% | -163.29% | 43.90% | 45.80% |
| Income Before Tax | 54.96% | -24.43% | -170.61% | 43.61% | 49.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.96% | -24.43% | -170.61% | 43.61% | 49.54% |
| Earnings from Discontinued Operations | 100.00% | 2,144.32% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.09% | 285.51% | -170.61% | 43.61% | 40.04% |
| EBIT | 22.12% | 34.58% | -163.29% | 43.90% | 45.80% |
| EBITDA | 21.59% | 35.28% | -158.62% | 45.02% | 46.92% |
| EPS Basic | 71.20% | 255.91% | -159.51% | 51.42% | 42.32% |
| Normalized Basic EPS | 104.56% | -4.57% | -159.53% | 51.55% | 51.44% |
| EPS Diluted | 70.23% | 255.79% | -161.11% | 51.42% | 42.30% |
| Normalized Diluted EPS | 104.56% | -4.57% | -160.51% | 51.55% | 51.44% |
| Average Basic Shares Outstanding | 31.66% | 18.99% | 18.64% | 16.08% | 3.96% |
| Average Diluted Shares Outstanding | 31.66% | 18.99% | 16.69% | 16.08% | 3.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |